About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fundExpands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500®Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting ...

AtaiBeckley Inc. ( ATAI ) is a clinical-stage company that develops psychedelic therapies for treatment-resistant depression (TRD) and social anxiety disorder (SAD). It was formed after a combination of Atai Life Sciences and Beckley Psytech. ATAI's pipeline includes BPL-003 for TRD, whichMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Ath ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study (NCT05660642) evaluating BPL-003 (mebufotenin benzoate nasal spray) in patients with treatment-resistant depression (TRD). Published in the Journal ...

AtaiBeckley Conference Call Summary Company Overview - **Company**: AtaiBeckley (NasdaqGM: ATAI) - **Focus**: Mental health conditions, particularly treatment-resistant depression (TRD) and social anxiety disorder (SAD) [2][3] Key Assets in Development 1. **BPL-003**: - **Type**: Intranasal formulation of mebufotenin (5-methoxy-DMT) - **Indication**: Treatment-resistant depression - **Phase**: Advanced, Phase 2b - **Efficacy**: - 8 mg dose showed superior efficacy compared to 12 mg in a Phase 2b study, with a 6.2-point change on the MADRS score compared to placebo [10][11][12][18] - Comparable efficacy to SPRAVATO with only one dose required [11][12] - Open label extension showed continued improvement and remission rates of about 80% [28][29] 2. **VLS-01**: - **Type**: Oral thin film formulation of DMT - **Indication**: Treatment-resistant depression - **Phase**: Phase 2b, currently ongoing with results expected in the second half of the year [133][153] 3. **EMP-01**: - **Type**: R-enantiomer of MDMA - **Indication**: Social anxiety disorder - **Phase**: Phase 2A, exploratory study showed comparable effects to SSRIs at 6 weeks [168][179] Mechanism of Action - **Psychedelic Compounds**: - All three assets are psychedelics that promote neuroplasticity and alter dysregulated circuits associated with depression and anxiety [8][9] - BPL-003 and VLS-01 are designed for short-duration effects, allowing for rapid patient discharge [31][32] Market Landscape - **Interventional Psychiatry**: - A shift from traditional psychiatry to interventional methods, emphasizing rapid symptom relief [222][226] - SPRAVATO has set a precedent in this space, generating approximately $1.7 billion in revenue last year, with expectations of $3 billion this year [240][241] Competitive Advantage - **Convenience**: - AtaiBeckley's products are designed for shorter treatment durations compared to existing options like SPRAVATO, which requires weekly dosing [252][259] - KOLs (Key Opinion Leaders) suggest a strong preference for AtaiBeckley's products due to reduced time commitment for patients [252][259] Infrastructure and Economics - **Current Treatment Sites**: - Approximately 5,000 to 6,000 sites in the U.S. are equipped to administer treatments, with around 600 sites responsible for 80% of revenue [270][272] - **Economic Model**: - AtaiBeckley aims to optimize clinic operations by allowing multiple patients to be treated in a day, enhancing revenue potential for treatment sites [346][348] Future Outlook - **Regulatory Path**: - Plans for two Phase 3 trials for BPL-003, with a focus on flexibility in dosing for physicians [75][76] - **Market Potential**: - The treatment-resistant depression market is estimated at around 3 million people, with current treatments only reaching about 3% of this population [309][311] Conclusion - AtaiBeckley is positioned to capitalize on the growing field of psychedelics in mental health treatment, with a strong pipeline of products that offer convenience and efficacy compared to existing therapies. The company is focused on addressing significant unmet needs in mental health, particularly in treatment-resistant depression and social anxiety disorder.

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - AtaiBeckley Inc. is advancing its clinical-stage biotechnology efforts, particularly focusing on BPL-003, a nasal spray for treatment-resistant depression (TRD), with plans to initiate Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA [1][4][5] Clinical Development - BPL-003 has received Breakthrough Therapy Designation and has shown positive Phase 2b results, indicating rapid antidepressant effects by Day 2 and sustained improvements for up to eight weeks [2][8] - The upcoming Phase 3 studies, ReConnection-1 and ReConnection-2, will consist of a 12-week randomized, double-blind, placebo-controlled core study, followed by a 52-week open-label extension [4][5] Financial and Operational Readiness - The company has reaffirmed its cash runway extending into early 2029, ensuring financial stability for ongoing and future clinical trials [3][7] - AtaiBeckley is advancing its commercial readiness strategy for BPL-003, aiming to integrate the treatment into existing psychiatric workflows without the need for in-session psychotherapy [5][6] Pipeline Progress - The company is also making progress with other pipeline candidates, including positive Phase 2a results for EMP-01 and anticipates topline data for VLS-01 in H2 2026 [3][7] Expert Perspectives - Discussions during the Investor Day highlighted the importance of streamlined treatment experiences and the potential for BPL-003 to expand patient access while maintaining clinical efficacy [9][10]

Core Insights - AtaiBeckley Inc. (NASDAQ:ATAI) is positioned as a promising penny stock following its strategic combination with Beckley Psytech and plans for a pivotal Phase 3 program for its BPL-003 nasal spray targeting treatment-resistant depression [1][4] Financial Performance - AtaiBeckley ended 2025 with $220.7 million in cash and equivalents, primarily due to equity-related issuances [3] - The company reported a net loss of $660 million for the year, largely attributed to a $530 million non-cash charge from the Beckley Psytech acquisition [3] Clinical Development - The BPL-003 nasal spray is set to initiate a Phase 3 pivotal program in Q2 2026, with results expected by early 2029 [1] - Positive clinical progress has been noted for the VLS-01 buccal film and EMP-01 for Social Anxiety Disorder, with VLS-01 Phase 2 topline data anticipated in H2 2026 [2] - EMP-01 has successfully met primary safety objectives in an exploratory Phase 2a trial and has received a new US patent, extending exclusivity through 2043 [2]

Core Viewpoint - AtaiBeckley Inc. is advancing its clinical programs, particularly BPL-003 for treatment-resistant depression, while showing revenue growth despite ongoing unprofitability [2][3][4]. Financial Performance - The company reported revenue of approximately $1.07 million in Q4 2025, which is an increase compared to the previous year but below some analyst expectations [3][5]. - Adjusted/non-GAAP EPS was approximately -$0.05, surpassing consensus estimates of -$0.12, while GAAP EPS was reported at -$1.73 due to non-cash merger-related charges [5]. - AtaiBeckley maintains a strong cash position of approximately $220.7 million as of December 31, 2025, providing a financial runway into early 2029 [5]. Clinical Development - The company is on track to initiate a Phase 3 pivotal program for BPL-003 in Q2 2026, which will include two trials targeting adults with treatment-resistant depression [3][4]. - Positive feedback from the FDA following the End-of-Phase 2 review supports the advancement of BPL-003 [3]. - Additionally, positive Phase 2a results for EMP-01 in Social Anxiety Disorder were reported [4]. Strategic Positioning - Following a strategic combination and redomiciliation in 2025, AtaiBeckley is focused on innovative mental health treatments [2]. - The company has low debt and high liquidity, which supports its continued development despite ongoing unprofitability [4].